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Introduction
The establishment of systems to ensure a safe and 
sufficient supply of blood and blood products for all 
patients requiring transfusion is a core issue of every 
blood programme. 
A spectrum of blood infectious agents is transmitted 
through transfusion of infected blood donated by 
apparently healthy and asymptomatic blood donors. 
Recent emerging-infectious-disease threats include West 
Nile virus1,2, chikungunya3, babesia4, dengue5, hepatitis 
E virus6, and variant of Creutzfeldt-Jakob disease7.
Parvovirus B19 (B19V), long known to be the 
causative agent of erythema infectiosum (fifth disease), 
is not a newly emerging agent. However, it deserves 
discussion because it may be present in blood and in 
plasma products, can circulate at extraordinarily high 
titres, can infect recipients, and, in some cases, can 
cause severe disease8. Its potentially severe pathological 
effects have become more apparent in the past decade 
with the widespread use of (pooled) plasma-derived 
medicinal products and are the main reason for the 
uneasy relationship between transfusion medicine 
specialists and B19V9. 
The aim of this review is to analyse the role played 
by this virus in compromising safety in transfusion 
medicine and the progressive measures to reduce the 
risks associated with the virus.
The virus
B19V, a member of the Parvoviridae family, 
Parvovirinae subfamily, Erythroparvovirus genus, and 
Primate erythroparvovirus 1 species10, is a small non-
enveloped DNA virus, discovered in 1975 by Yvonne 
Cossart in the blood of a healthy blood donor11. The 
name parvovirus originates from the Latin word parvum, 
which means small. In fact, parvoviruses are among the 
smallest known viruses with a virion diameter of 18-26 
nm12. Their structure is simple: the icosahedral virion 
consists only of proteins and linear single-stranded-
DNA genome (length 5-6 kb) with hairpin structures 
at both ends. The hairpins are palindromic and the 
3′-end can fold and function as a primer during viral 
replication12 (Figure 1). Three B19V genotypes have 
been identified based on isolates having nucleotide 
divergence greater than 10%. Genotype 1 is the most 
prevalent type currently circulating worldwide and is the 
B19V prototype13. It largely replaced genotype 2 viruses, 
which were common in Europe half a century ago14 
and, therefore, has been sporadically found in plasma 
donations from Europe and North America15. Genotype 
3 has been found predominantly in West Africa (Ghana) 
thus implying a different and longer evolutionary history, 
probably rooted in Africa16. Interestingly, recent studies 
found B19V genotype 3 in samples from Europe, Asia, 
and Brazil thus raising the question that this genotype 
may be more widely distributed outside Africa than 
previously believed17. 
In its infection cycle, the virus links to a specific 
receptor on the surface of host cells18 (i.e. P blood group 
antigen globoside-4 [Gb4] in the case of human B19V)
and is transported into the cell by endocytosis. Inside the 
host cell, the virion is transported to the nucleus where its 
Figure 1 - Schematic representation of Parvovirus B19 icosahedral virion and genome structure.
 ORF: open reading Frame; kDa: kiloDaltons; X: Region X.
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replication takes place. Parvoviruses do not encode their 
own DNA-polymerase and are, therefore, all dependent on 
host cell polymerase and the S-phase of dividing cells12. 
Gb4 is also responsible for the phenomenon of B19V 
haemagglutination19. Individuals who lack the blood 
group P antigen on their erythroid cells are not, therefore, 
susceptible to B19V infection20. The B19V receptor is also 
present on platelets, cardiac, synovial, renal and thyroid 
cells as well as on hepatic progenitors8. Interestingly, 
between 1989 and 1992, B19V replication was shown in 
a primary culture of erythroid cells derived from foetal 
liver21, in haematopoietic progenitor cells from a blood 
donor22, and in human umbilical cord blood cells23. 
The bone marrow cell tropism of B19V is now well 
recognised as an erythroid progenitor cell tropism24. In 
fact, erythroid progenitor cells are susceptible to infection 
and this susceptibility increases with differentiation. 
Therefore, the destruction of the source of mature red 
blood cells will result in dramatically low haematocrit 
levels and a temporary state of anaemia. Naturally, in 
patients with disorders that shorten red blood cell half-
life the clinical picture can be more severe and there may 
also be a transient aplastic crisis20. On the other hand, the 
concentration of Gb4 on non-haematopoietic tissues 
does not appear sufficient for active infection, and 
other factors may be required for virus internalisation 
and replication19. 
Markers of Parvovirus B19 infection
B19V viraemia occurs 1 week after exposure and 
usually lasts about 5 days, with virus titres peaking in 
the first 2 days (Figure 2). IgM antibodies against B19V 
are detected late in the viraemic stage. They appear 10 
to 14 days after the infection and can persist for up to 5 
months but, in some patients, they can last even longer 
(Figure 2)25. Specific IgG antibodies are detectable about 
15 days after infection, remain high for several months 
and persist long-term25.
Parvovirus serology (anti-B19V immunoglobulin 
[Ig] M and IgG antibodies) can be determined 
using enzyme-l inked immunosorbent  assay 
(ELISA), radioimmunoassay, chemiluminescence or 
immunofluorescence25. 
IgA antibodies are also detectable for a short period 
and may play a protective role in the respiratory tract26. 
In addition, long-term B19V-specific IgE antibodies 
have been found, but their biological functions are 
unclear27. 
Figure 2 -  Clinical, haematological and viral course after B19V infection in immunocompetent subjects.
 B19V: Parvovirus B19; IgG: immunoglobulin G; IgM: immunoglobulin M.
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Given that there are different epidemiological 
patterns of infection, the seroprevalence of B19V-
IgG varies widely from approximately 2% to 21% in 
children from 1 to 5 years of age, from 30% to 40% 
in adolescents, from 40% to 60% in adults, and more 
than 85% in elderly populations28,29. Neutralising IgG 
antibodies generally appear about 2 weeks after infection 
and persist lifelong (Figure 2). The development of 
the antibody response corresponds to virus clearance 
and also, in the vast majority of immunocompetent 
individuals, protection from disease25. The protective 
role of antibodies against B19V is demonstrated by the 
efficacy of commercial immunoglobulins used to treat 
B19V infection in immunocompromised subjects, in 
whom, due to the absence of antibodies, viral levels can 
be even higher than 1012 copies/mL30. 
Results of IgM testing are particularly difficult 
to interpret31. Standardisation among laboratories is 
lacking. Even in a single laboratory, sensitivity and 
specificity partly depend on the operator's skills. High-
level viraemia in acutely infected subjects may cause 
virus-antibody complexes, which will result in a false-
negative IgM test result31. 
In this setting, polymerase chain reaction (PCR) 
analysis or alternative nucleic acid amplification 
technology (NAT) assay (e.g., transcription-mediated 
amplification) may be a better diagnostic tool as viral 
titres can reach more than 1012 genome equivalents (geq) 
per mL during acute B19V infection. On the other hand, 
in chronic B19V infection, viral DNA can persist in the 
host without the presence of B19V IgM or IgG. In the 
immunocompetent host, viral DNA is detectable for 
at least 1 month after infection30, but can persist even 
longer at low levels32. Therefore, B19V DNA, detected 
by qualitative PCR analysis, is not always indicative of 
recent infection25. This assay has been set up to include 
an internal control to eliminate false negative results 
caused by the presence of inhibitors in plasma. It is very 
useful for plasma pools for fractionation and could also 
be exploited for clinical diagnosis in primary red cell 
aplasia, in which the antibody response is depressed, 
or for the detection of recently discovered variant 
erythroviruses in human disease33. 
Finally, as far as the identification of B19V genotypes 
2 and 3 is concerned, many commercial and in-house 
PCR methods have shown lower sensitivity or failure 
to detect either or both of these genotypes12,15.
Clinical features and therapy
Many individuals with B19V infection are 
asymptomatic (about 25% of adults and 50% of children 
during an outbreak), or manifest mild, non-specific, 
cold-like symptoms that are never linked to the virus34,35 
(Figure 2). Most patients with B19V infection do not 
require laboratory tests or therapy because symptoms 
are mild and the illness resolves over 5-7 days.
The pattern of clinical disease is strongly influenced 
by the haematological and immunological status of 
the host36. B19V infection may have a serious clinical 
outcome in three categories of susceptible recipients: 
(i) patients with shortened red cell survival (e.g. those 
with thalassaemia major, sickle cell disease, or other 
haemolytic diseases); (ii) immunocompromised patients 
(whether previously exposed to B19V or not); and (iii) 
pregnant women.
The most common clinical manifestation in children, 
especially those aged 4-11 years, is erythema infectiosum 
causing a "slapped-cheek" facial rash, extending later to 
the trunk and limbs ("gloves and socks" syndrome) and 
accompanied, in a few cases, by fever, headache, coryza, 
nausea, and diarrhoea. Joint involvement, transient 
haemolytic anaemia, and encephalitis may also occur. 
In adults, polyarthropathy characterised by sudden 
symmetrical arthralgia is more common than rash. 
Some patients may present acute anaemia but those 
with underlying haemolytic disorders may develop a 
transient aplastic crisis37. Persistent B19V infection 
can also cause severe anaemia. The first patient 
recognised to have this condition had an underlying 
combined B- and T-cell immunodeficiency with low 
immunoglobulin levels (Nezelof syndrome)38. Patients 
with human immunodeficiency virus (HIV) infection can 
also develop pure red blood cell aplasia due to B19V 
infection; in these patients, B19V titres can be as high 
as 1012 copies/mL. 
During pregnancy (weeks 9 to 20) B19V infection is 
associated with an approximately 10% incidence of foetal 
loss, which is rare after the 20th week. B19V infection of 
foetal cardiac tissue may lead to myocarditis and heart 
failure, which can result in a hydrops foetalis, neurological 
foetal abnormalities, or congenital anaemia34. 
Other complications associated with B19V 
infection include encephalopathy, epilepsy, meningitis, 
myocarditis, dilated cardiomyopathy, and autoimmune 
hepatitis34. 
There are no specific antiviral drugs or vaccines against 
human parvovirus infection. The (aplastic) anaemia can 
be treated through intravenous immunoglobulin therapy, 
possibly repeated in chronic and persistent infections25, 
or red blood cell transfusion, when necessary39. On the 
other hand, in immunocompetent patients, treatment is 
unnecessary and infections are self-clearing. 
Virus transmission and blood product safety
Human B19V circulates worldwide, is mildly 
contagious, and may occur sporadically or in epidemics. 
In temperate climates, epidemic manifestations occur 
more commonly in late winter, spring or early summer36. 
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B19V is mainly transmitted through the respiratory 
route and its DNA is contained in respiratory secretions 
at the time of viraemia, when infectivity is highest40. 
Transmission in the household, at day care, and in school 
is common, although the virus can also be transmitted 
vertically41 and via blood transfusion and organ/bone 
marrow transplantation14. 
The risk of vertical transmission varies between 33% 
and 51% following acute infection of pregnant women 
with reported adverse foetal outcomes in 3% to 12% of 
cases41. There is evidence that transmission of severe 
B19V infection may occur at the time of solid organ 
or haematopoietic transplantation and cause serious 
complications such as aplastic crises, pneumonia, and 
multiorgan failure42-45. Iatrogenic transmission of B19V 
through blood products is possible because high-level 
viraemia regularly occurs during primary infection and 
more than 1012 geq/mL are often found in the blood of 
asymptomatic individuals during the early phase of 
acute infection46. 
Plasma-derived medicinal products
Although there have been very few reports of 
clinically relevant B19V infection resulting from 
the transfusion of a blood component containing the 
virus47, B19V is a frequent contaminant of blood and 
plasma donations and has been transmitted by plasma-
derived medicinal products13,48,49. Interestingly, both a 
temporal correlation between infusion of plasma-derived 
medicinal products and viraemia, seroconversion and/or 
non-clinically significant infections and blood product 
viral contamination have been documented. Other 
studies showed that the prevalence of B19V-specific 
antibodies was much higher in groups receiving clotting 
factors than in control groups50. 
Transmission via plasma-derived medicinal products 
can occur because of incomplete physiological clearance 
of virus, high-level viraemia in acutely infected 
individuals14, and the resistance of B19V to most viral 
inactivation procedures used in the manufacturing of 
blood-derived products51-55.
B19V is a good model for new emergent viruses 
capable of infecting blood products because of their 
properties of physical resistance. In fact, B19V DNA 
is detectable in 50% to 80% of non-virally inactivated 
factor VIII concentrates and in 30% to 50% of 
solvent/detergent-inactivated factor IX concentrates, 
respectively12,56. B19V was also detected in two of three 
unheated batches of clotting factor preparations and 
in 20% to 25% of solvent/detergent-treated batches, 
while the fractionation process used to obtain albumin 
preparations is apparently more efficient at eliminating 
the virus57-62. B19V DNA sequences were also detected 
in 16%63 to 28%64 of factor VIII concentrates. A more 
recent German study detected B19V DNA in 26% of 
different coagulation factor concentrates produced 
between 2007 and 200865. Soucie and colleagues found 
that compared to populations not exposed to blood 
or blood products, the studied population receiving 
plasma-derived medicinal products was 1.7 times 
more likely to have IgG antibodies to B19V66. Another 
study demonstrated that, overall, 25% of albumin 
samples, 100% of factor VIII concentrates, and 20% of 
intravenous and 75% of intramuscular immunoglobulin 
preparations contained B19V DNA67. The viral load in 
those samples ranged from 1×102 to 1×106 geq/mL. Alter 
et al. reported a high prevalence (over 60%) of B19V 
DNA in factor IX, factor VIII, and prothrombin complex 
concentrates, as well as plasma pools with viral loads of 
1×102 to 1×108 geq/mL9. 
In conclusion, the multiple reports of B19V 
transmission by pooled-plasma products were almost 
always documented by recipient seroconversion in 
asymptomatic cases and less frequently by clinical 
diagnosis of B19V-related disease associated with 
positive B19V test results68. It is also worth noting that 
according to a recent interim report from a prospective 
clinical study on the incidence of factor VIII inhibitors 
in previously untreated patients during prophylaxis, 
on-demand treatment, and surgical procedures with a 
plasma-derived, human, von Willebrand factor-stabilised 
FVIII product, the 57 adverse events rated "serious" 
probably or possibly related to factor VIII treatment 
reported in 24 subjects also included 14 cases of 
asymptomatic parvovirus B19 seroconversion69.
Inactivation/removal steps and B19V
In order to obtain safe plasma-derived medicinal 
products, the processes to produce these products 
include steps to inactivate or remove viruses. B19V 
has been shown to be susceptible to chromatography, 
pasteurisation (10 hours at 60 °C), steam (vapour 
heat), exposure to pH 4 (occasionally used during the 
manufacture of immunoglobulins), and (only partially)55 
to small-pore-size nanofiltration70. It was shown that 
porcine parvovirus (a model for human parvovirus B19) 
could be effectively inactivated with riboflavin/UV light 
suggesting that B19V could also be inactivated. On the 
other hand, amotosalen/UVA light is not effective on 
porcine parvovirus; its limited effectiveness against 
certain of these viruses was demonstrated when 
transmission of hepatitis E virus occurred via transfusion 
of a plasma product. Levels of viral load of non-lipid-
enveloped viruses, such as B19V, could be reduced by 
4 log or more through methylene blue treatment, while 
other viruses, such as hepatitis A virus, are not affected70. 
Transfusion transmission of B19V was also reported 
with solvent/detergent-treated plasma54. 
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Relationship between viral load in plasma and 
probability of transmission by blood products
To date, no B19V transmission from pooled-plasma 
products has been documented when less than 103 to 104 
IU/mL B19V DNA are present in an infused product13. 
There is still some doubt as to the reason for this lack 
of infectivity. It may be due to an inadequate amount 
of infused infectious virions, a neutralising effect from 
B19V antibodies present in other plasma units contained 
in the plasma pool, or a combination of these factors. 
Recipient factors may also play a role because it has 
been reported that B19V antibodies protect against 
B19V re-infection, and most of the adult population is 
B19V-seropositive as a result of previous infection71. 
To reduce the potential risk of transmission, the US 
Food and Drug Administration proposed a limit of 104 
geq/mL for the production of plasma pools destined 
for all plasma derivatives72. Similarly, the European 
Pharmacopoeia has imposed a limit of 104 UI/mL of B19V 
in anti-D immunoglobulins and pooled virus-inactivated 
plasma73.
 
Labile blood products
As far as cellular blood products are concerned, 
B19V DNA levels lower than 104 IU/mL might not be 
clinically significant while the transfusion of labile blood 
products with B19V titres greater than 107 IU/mL has 
been associated with transmission of B19V infection13,25. 
However, susceptibility to infection could be highly 
dependent on the presence or absence of neutralising 
antibodies in the recipient74. Symptomatic infections 
have been reported in a few case series and linked donor-
recipient studies have confirmed that in most cases 
B19V transfusion-transmitted infections are clinically 
irrelevant68 while vulnerability to serious B19V-related 
haematological disorders is dependent on the patients' 
underlying diseases50. 
Studies in different countries found B19V DNA in 
1% of all blood cell preparations and blood products 
transfused to patients in a haematology ward49, in 0.9% 
of standard blood components49 (in 2% of pooled-plasma 
products and in 0.7% of single-donor products)49, in 
0.006% of blood donations75, in 0.14% of single-donor 
blood products76, and in 0.16% of plasma samples77. 
The prevalence of B19V DNA in plasma pools ranged 
from 0.024%78 to 97%79. Interestingly, another study 
demonstrated that, overall, 85% (60% to 100% depending 
on the manufacturer) of plasma pools contained B19V 
DNA67. The percentage of the plasma pools positive for 
B19V DNA that were also positive for IgG was 100%79,80, 
while the percentage of the same plasma pools also 
positive for IgM ranged from 23%80 to 65%79.
There are several reasons for the very different 
figures in diverse studies: first, the epidemiological 
settings are different; second, the rates of detectable viral 
DNA are related to the sensitivity of the methods used; 
and third, there are seasonal variations in transmission 
and, therefore, in viraemia49.
 
Strategies for screening donors or plasma pools
Since April 2000, all blood donations started to 
be screened by a B19V minipool real-time NAT in 
German Red Cross Centres and four areas in Austria51. 
Since 2004, Polish blood donors have also been tested 
for B19V DNA. Screening has been performed in 
donors of plasma for fractionation for anti-D and 
anti-HBs production, and donors of erythrocytes used 
for immunisation81. In 2008, to reduce the risk of 
B19V transmission through contaminated blood for 
transfusion and plasma-derived medicinal products, 
Japanese Red Cross Blood Centres introduced B19V 
antigen screening by chemiluminescent enzyme 
immunoassay for all donated blood. This test has 
a sensitivity of approximately 107 IU/mL. Positive 
samples are then excluded from the 20-pool-screening 
triple NAT to reduce the risk of cross-contamination 
during NAT82. There has been a subsequent expansion 
of B19V DNA screening of pools of plasma used to 
manufacture plasma derivatives in many countries83. 
The combined strategy of high-titre-B19V PCR 
screening and viral decontamination during the plasma 
manufacturing process has significantly increased the 
margin of B19V safety of plasma-derived medicinal 
products84.
 
Prevalence of B19V in blood donors and patients
Blood donor screening for B19V is feasible using 
B19V antigen assays or NAT. Many commercial or 
in-house real-time NAT systems are available83. The 
risk of exposure to a high-load B19V viraemia during a 
window period is relatively small, but during epidemic 
periods, the incidence of parvovirus in the blood can 
be as high as one in 260 donors85. 
Several studies published between 1995 and 
201416,51,68,78-82,84,86-117 show that the prevalence of B19V 
in blood donor populations ranges from 6%92 to 79.1%112 
for IgG (92% in donors older than 61 years101), from 
0.72%98 to 7.53%96 for IgM, from 0.01%82 to 15.3%87 
for IgM+IgG, and from 0%89 to 1.3%16,89,102 for B19V 
DNA (see Table Ia and Table Ib). 
Table II lists several studies, published between 1988 
and 2013, on the prevalence of B19V in patients with 
congenital bleeding disorders66,118-127. The prevalence of 
B19V in these patients ranged from 31%126 to 97%123. 
Interestingly, the range for each specific disorder was 
from 21%120 to 93%123 for haemophilia A, from 35.5%66 
to 97%123 for haemophilia B, and from 37.9%66 to 
80%123for von Willebrand disease.
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 Table Ia - Prevalence of parvovirus B19 reported in blood donors, blood donations and plasma pools.
Continent Country Prevalence Subject of study Study author 
and year of publication
IgG 
(%)
IgM 
(%)
IgM+IgG 
(%)
B19V DNA
 (%)
AFRICA Ghana - - - 0.8 Blood donors Compston LI, 200886
AMERICA Canada 24.3 4.7 15.3 - Blood donors Wasfi S, 199687
Brazil 60 - - 1 Blood donors Slavov SN, 201288
Brazil 57.4 - - 0 Blood donors Slavov SN, 201289
Chile - - - 0.84 Blood donors Lévican J, 201190
Chile 54.8 - - - Blood donors Gaggero A, 200791
USA 6 - - - Blood donors O'Bryan TA, 201092
- - - 0.84 Blood donors Kleinman SH, 200968
- 1 - - Blood donors Doyle S, 200093
- - - 0.88 
(100: IgG+
 23: IgM+)
Blood donations Kleinman SH, 200780
ASIA China - - a) 54  
(100: IgG+ 
65.6: IgM+) 
b) 97 
c) 21.6
a) Plasma pools; 
b) apheresis 
donors; 
c) plasma 
derivatives
Zhang W, 201279
24.6 6.9 2.5 0.58 Blood donors Ke L, 201194
55.43 - - - Blood donors Wei Q, 200695
India 27.96 7.53 2.40 - Blood donors Kumar S, 201396
39.9 - - - Blood donors Kishore J, 201097
Japan - - 0.01 0.04 Blood donors Sakata H, 201382
67.9 0.72 - 0.2 Blood donors Ihara T, 201398
- - - 0.01 Blood donors Matsukura H, 200899
- - 0.11 - Blood donors Wakamatsu C, 1999100
40 (donors 16-30 years old) 
92 (donors >61 years old)
- - 0.250 Blood donors Tsujimura M, 1995101
Saudi Arabia 39.3 0 44.6 0 Blood donors Obeid OE, 2011102
South Korea - - 60.1 0.1 Blood donors Oh DJ, 2010103
Thailand 20.16 - - - Blood donors, 
children
Poovorawan Y, 2000104
B19V: parvovirus B19; IgG+: immunoglobin G positivity; IgM+: immunoglobin M positivity; IgG&IgM+: immunoglobin G and immunoglobin M positivity; 
geq/mL: genome equivalents/mL.
Other parvoviruses, blood donors, and blood 
products
B19V was considered to be the only human 
pathogenic parvovirus until the recent discovery of 
Bocaparvoviruses and Parvovirus 4 (PARV4), whose 
epidemiology and disease association are still poorly 
understood128. 
PARV4 is a member of the Primate Tetraparvovirus 
1 species10, Parvoviridae family, discovered in 2005 in 
plasma from an intravenous drug user, with symptoms 
consistent with acute HIV infection but who was 
confirmed to be HIV-RNA negative129. A related virus 
variant Parvovirus 5 (PARV5) was identified in plasma 
pools used in the manufacturing process of plasma-
derived medicinal products130. Later, the name PARV5 was 
changed to PARV4 genotype 2. In 2008, a third genotype 
of PARV4 was found in two patients in sub-Saharan 
Africa with acquired immune deficiency syndrome131; 
non-parenteral transmission might contribute to its 
transmission in this area132. The virus was detected in 
plasma pools used in the manufacturing process of 
plasma-derived medicinal products, particularly those 
from the United States129,133 and Asia134, and also in 
clotting factor concentrates, namely preparations of factor 
VIII and IX134,135. In contrast, three studies carried out in 
France and Germany did not detect any PARV4 DNA 
positive samples in a large number of plasma donations, 
minipools or coagulation factor concentrates65,136; it is still 
unclear whether these negative results have seasonal or 
geographical explanations12.
Interestingly, products manufactured in the early 
1970s were found to be positive for PARV4, and in 
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general, older concentrates were found to be more 
frequently contaminated with PARV4137. This could be 
due either to differences in population-based hazard of 
infection over time or to improvements in manufacturing 
processes12. 
Several studies have subsequently found PARV4 
in intravenous drug users in Europe, Asia, and the 
United States as well as in men who have sex with men 
and in febrile patients138-141. Such cases are indicative 
of blood-borne transmission of PARV4. The virus 
has also been detected in blood donors in the United 
States, South East Asia, and Europe65,130,133-135,138,141-150 
(Table III). The prevalence of PARV4 in blood donor 
populations is not clear; studies carried out in France 
found that the prevalence of PARV4-DNA ranged 
from 0%145 to 24%148 in donors and from 4%134 to 
26.15%133 in plasma-derived medicinal products. The 
high frequency of detection of PARV4 DNA reported 
in some articles65,133,148,149 may be the result of seasonal 
and/or geographical epidemiological variation or lack 
of standardisation of detection methods.
Very little information is available regarding the 
clinical significance of infection with PARV4; so far, 
in a study of acutely infected persons with haemophilia 
the only repeatedly observed clinical presentation was 
a rash in three subjects and unexplained hepatitis in two 
patients151.
Among  Bocaparvov i ruses ,  t he  Pr imate 
Bocaparvovirus 1 species includes human bocavirus 
1 (HBoV1)10, which was identified in 2005 in 
nasopharyngeal aspirates of children with respiratory 
tract infections152. Although the routes of transmission 
of Primate Bocaparvoviruses are unknown, many 
parvoviruses are transmitted by inhalation or contact 
with infectious sputum, faeces, or urine. HBoV1 is 
predominantly a respiratory pathogen, whereas three 
Table Ib - Prevalence of parvovirus B19 reported in blood donors, blood donations and plasma pools.
Continent Country Prevalence Subject of study Study author 
and year of publication
IgG 
(%)
IgM 
(%)
IgM+IgG 
(%)
B19V DNA
 (%)
EUROPE Belgium - - - 0.16 Blood donors Thomas I, 2003105
France - - - 0.024 Plasma pools Petermann R, 201078
Germany 0.88 - - 0.014 Blood donations Hitzler WE, 2002106
- - - 0.125 Blood donations Weimer T, 200184
- - - 0.66 Blood donors Juhl D, 2014107
The Netherlands - - - 0.006 
(0: IgG+ 
24: IgM+ 
6: IgG&IgM+)
Blood donors, 
plasma pools
Kooistra K, 2010108
- - - 0.005
(70: IgG&IgM+)
Blood donors Corcoran A, 2007109
- - - 47 Plasma pools Zaaijer HL, 2004110
Italy - - - 0.89 Mini-pools Gessoni G, 2007111
79.1 - - - Blood donors Manaresi E, 2004112
Poland 0.10 Blood donors Grabarczyck P, 201281
Portugal - - - 0.12 Blood donors Henriques I, 2005 113
Russia - - - 1 
(100: IgG+ 
1 case: IgM+)
Blood donors Filatova EV, 2010114
Spain 64.7 0 - - Blood donors Munoz S, 1998115
9.78 - - - Blood donors Mata Rebon M, 1998116
OTHER 
COUNTRIES
UK, Ghana, 
South Africa, 
and Malawi 
- - - 0.9 UK 
1.3 Ghana 
0.55 S. Africa 
1.25 Malawi
Blood donors Candotti D 200416
Germany and 
Austria
- - - 0.0127 >105 geq/mL 
0.26<105 geq/mL
Blood donors Schmidt M, 200751
Belgium and 
Tunisia
Belgium: 74 
Tunisia: 65
- - - Blood donors Letaïef M, 1997117
B19V: parvovirus B19; IgG+: immunoglobin G positivity; IgM+: immunoglobin M positivity; IgG&IgM+: immunoglobin G and immunoglobin M positivity; 
geq/mL: genome equivalents/mL.
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additional species (HBoV2, HBoV3, and HBoV4) 
have been found mainly in stool. A variety of signs 
and symptoms have been described in patients with 
HBoV infection, including rhinitis, pharyngitis, 
cough, dyspnoea, wheezing, pneumonia, acute otitis 
media, fever, nausea, vomiting, and diarrhoea153. The 
rate of nosocomial respiratory acquisition may be as 
high as 18% in hospitalised HBoV1 cases, and up to 
19% of nosocomial acute respiratory tract infections 
are HBoV1 positive. Intrauterine infection is unlikely 
because of the high degree of immunity in pregnant 
women153. The seroprevalence of HBoV1 has been 
reported to be more than 90% in adults. However, the 
HBoV1-4 viral-like particles used in the ELISA have 
shown cross-reactivity, which might affect serological 
assays. Norja et al. found that the seroprevalence of 
HBoV1 was 94.9% but after removing cross-reacting 
antibodies the rate dropped to 68.4%154. Similar 
results were obtained by Kantola et al.155, who 
observed that the seroprevalence of HBoV1 in adults 
decreased, from 96% to 59%, after removing the cross-
reacting antibodies. The Kantola study found that the 
seroprelavence of HBoV in adults was 34% for HBoV2, 
15% for HBoV3, and 2% for HBoV4155. 
Interestingly, three studies in blood donors and 
plasma-derived medicinal products failed to detect 
HBoV1 DNA65,133,136. This may be due to the higher 
frequency of HBoV1 infections among young 
children than in blood donors or to low-level viraemia 
undetectable in large plasma pools12. As seroprevalence 
studies on blood donors and blood products are limited, 
this issue could be an interesting and useful subject of 
investigation for the near future. 
Conclusions
Transfusion-transmitted human B19V is a classic 
example of an unresolved issue for the transfusion 
medicine community. The strategies used by plasma 
fractionators and competent authorities to ensure the 
safety of plasma-derived medicinal products include 
NAT screening of single donations and mini-pools and 
the adoption of multiple steps of viral inactivation and 
removal with solvent/detergent, super-heating (at 80 °C 
for 3 days), pasteurisation, and nano-filtration156. 
The current strategy of B19V-NAT plasma mini-
pool screening might not be completely effective 
at preventing the transmission of B19V and, more 
importantly, would not detect other new or emerging 
Table II - Prevalence of parvovirus B19 reported in blood product recipients with bleeding disorders.
Prevalence of B19V antibody 
(%)
Subjects of study Study author 
and year of publication
a) Haemophilia A: 42.1 
b) Haemophilia B: 35.5 
c) vWD: 37.9 
d) Rare factor deficiencies: 55.8
Patients with bleeding disorders Soucie JM, 201366
Haemophilia: 64.2 Patients with haemophilia, malignant disease, immunodeficiency 
diseases, common gynaecological ailments, pregnant women 
and children with malignant diseases.
Reinheimer C, 2010118
91.8 Patients with haemophilia Langara H, 2005119
21 to 48.5 Patients with haemophilia A Soucie JM, 2004120
a) Haemophilia A: 79.2 
b) Haemophilia B: 83.3 
c) Controls: 34.6 
IgM was found in 2 patients with haemophilia. 
No B19V DNA was found.
Patients with haemophilia Brojer E, 1999121
76.7 Patients with bleeding disorders Canales MA, 1998122
a) Haemophilia A: 93 
b) Haemophilia B: 97 
c) vWD: 80 
Total 93
Patients with bleeding disorders Mauser-Bunschoten EP, 1998123
IgG: 84 
IgM: 0
Patients with bleeding disorders Aguilar Franco C 1997124
81.6 Patients with haemophilia Ragni MV, 1996125
a) Haemophiliacs: 31 
b) Controls: 5
Patients with haemophilic arthritis Zakrzewska K, 2001126
a) Haemophiliacs: 
55.5 Heated products 
93.3 Unheated products 
b) Healthy donors: 29.3
Patients with haemophilia and healthy donors Bartolomei Corsi O, 1988127
B19V: parvovirus B19; vWD: von Willebrand disease.
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viruses with similar characteristics that could pose a 
hazard to the users of these products. 
The universal screening of donated blood for B19V by 
NAT-based algorithms is currently carried out in Poland81, 
Germany (German Red Cross Centres)51, Austria51 and 
Japan82. The detection limit set at 105 IU/mL is undoubtedly 
contributing to the decrease not only of the viral load 
in pooled source plasma but also of the frequency of 
seroconversion or symptomatic infection after treatment 
with blood products. 
The implementation of NAT screening with a much 
higher sensitivity for B19V is unlikely as it would 
result in a considerable number of components being 
discarded, thus jeopardising the capacity of blood 
systems to ensure self-sufficiency of blood and blood 
products. 
In the near future the transmissibility of B19V 
by transfusion could be better clarified by taking 
into account not only the level of B19V in the blood 
product and its overall transfused dose but also the 
presence of anti-B19V antibodies, their potency, and 
titre. Donors with persistent IgG anti-B19V might 
be considered "B19V-safe" for single-donor blood 
components157. Another strategy currently recommended 
in the Netherlands is based on the identification of 
negligible B19V infectivity and the definition of selected 
indications for the transfusion of a "B19V-safe" blood 
component (i.e. a blood component donated by a donor 
in whom "IgG antibodies against B19V have been 
detected in two separate blood samples, one taken at 
least six months after the other")157. 
Other factors to be considered are the immune and 
anti-B19V status of the recipient as well as his/her B19V 
infection history, which can influence viral persistence. 
In addition, the approach to high-risk patients requires 
particular care. 
However, as the extent of clinical disease due to 
transfusion transmission is unknown and reported 
infrequently, the benefits of (universal) B19V-blood-
donor screening may be minimal and, at the moment, not 
justified, especially in countries with low endemicity158. 
For the immediate future PARV4 is likely to remain 
under suspicion as a cause of different symptoms in 
subsets of infected individuals. Continued evaluation 
of the incidence of PARV4 in treated individuals 
and disease associations of PARV4 infections is also 
required to support decision making on whether costly 
measures such as testing and excluding PARV4-
positive donations from fresh blood inventories should 
be implemented. 
Table III - PARV4 DNA findings by PCR in blood donors or plasma-derived medicinal products.
PARV4 DNA (%) Subjects of study Study author 
and year of publication
5.1 Plasma donations Fryer JF, 2006142
a) 8.7 
b) 4
a) Healthy donors, febrile patients, IDUs,
b) plasma pools
Fryer JF, 2007130
16 
pre-1990 23% 
1990-2005 2%
Factor VIII concentrates collected from 1974 to 2005 Fryer JF, 2007134
11.5 HCV positive subjects and/or IDU Fryer JF, 2007138
5.3 IDU, blood donors negative for HIV, HCV and HBV Lurcharchaiwong W, 2008141
12.4 Coagulation factor concentrates Schneider B, 2008135
a) 1 
b) 1.2 
c) 0 
d) 1.6
a) Blood donors, 
b) patients with suspected viral diseases, 
c) BM/PBSC transplant recipients, 
d) kidney transplant recipients
Vallerini D, 2008143
3.8 Healthy blood and skin donors, skin donors with dermatological disease Botto S, 2009144
0 Transfused immunocompetent patients, blood donors Servant-Delmas A, 2009145
1.7 HCV, HIV, and HBV positive subjects Tuke PW, 2010146
8.6 Infants (Ghana) Panning M, 2010147
24 Blood donors Touinssi M, 2010148
24.5 Haemodialysis patients positive or not for HBV markers, lung transplant recipients Touinssi M, 2011149
26 Plasma donations Modrow S, 201165
26.15 Blood donors Ma YY, 2012133
0 
(4.76 IgG)
Blood donors Maple PA, 2013150
PCR: polymerase chain reaction; IDU: intravenous drug users; HIV: human immunodeficiency virus; HCV: hepatitis C virus; HBV: hepatitis B virus; 
BM: bone marrow; PBSC: peripheral blood stem cell.
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At the moment, the pathological role, clinical 
relevance, and epidemiology of HBoV1 remain unclear 
thus making any assessment of its possible role in blood-
product safety speculative.
Keywords: Parvovirus B19, Parvovirus B19 prevalence, 
transfusion-transmitted Parvovirus B19, blood product 
safety, plasma-derived medicinal product.
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